Savara (SVRA) Other financing activities (2010 - 2026)
Savara (SVRA) posted quarterly Other financing activities of $45000.0 for Q1 2026, down 72.73% year-over-year from $165000.0 in Q1 2025, and down 61.54% quarter-over-quarter from $117000.0 in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Other financing activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Other financing activities for 14 consecutive years, with $45000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 72.73% year-over-year to $45000.0; the TTM figure through Mar 2026 stood at $227000.0 (up 87.6% YoY), while the FY2025 annual figure was $347000.0, up 4857.14% from the prior year.
- Other financing activities declined to $45000.0 in Q1 2026 per SVRA's latest filing, from $117000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $237000.0 in Q3 2024 and bottomed at -$292000.0 in Q4 2024.
- Historically, Other financing activities has averaged $56833.3 across 4 years, with a median of $64000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities tumbled 428.09% — and 2025, when it soared 490.91%.
- Savara's Other financing activities stood at $89000.0 in 2023, then sank by 428.09% to -$292000.0 in 2024, then surged by 140.07% to $117000.0 in 2025, then slumped by 61.54% to $45000.0 in 2026.
- Business Quant data shows SVRA's Other financing activities at $45000.0 in Q1 2026, $117000.0 in Q4 2025, and $65000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 194,000.00 |
| Mar 31, 2026 | 45,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Dec 31, 2024 | 48,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 63,000.00 |
| Jun 30, 2023 | 104,000.00 |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Jun 30, 2020 | 38,000.00 |
| Mar 31, 2020 | 48,000.00 |
| Sep 30, 2019 | 44,000.00 |